Connect Biopharma’s Latest Dermatitis Drug Update Fails to Pump Up Shares
Company’s stock sank after it released data on Phase 2b trials for its atopic dermatitis drug, a potential competitor to Regeneron-Sanofi blockbuster Dupixent Key takeaways: Loss-making Connect Biopharma says Phase…
RELATED ARTICLES
-
Kintor shares plunge after hair-loss drug flops in clinical trials
9939.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
HBM gets health boost from drug licensing deals
2142.HK
-
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK
-
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
Discover hidden China stock gems in our weekly newsletter